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ABSTRACT
Vitamin D3 (VD3) and its steroidal nuclear receptor are necessary for proper development of a pregnancy. They play a key 
role in implantation, modulate the mother’s immune response to the developing fetus, influence the final development 
of a placenta, and regulate blood pressure and glucose tolerance. VD3 deficiency can lead to the occurrence of obstetric 
complications such as recurrent miscarriages, preeclampsia, intrauterine growth restriction, gestational diabetes and preterm 
labor. VD3 deficiency is a common phenomenon across the globe; because of the higher demand placed on their bodies, 
pregnant women are more likely to develop VD3 deficiency. During pregnancy, VD3 supplementation is a safe method of 
treatment without risk of side effects or intoxication. To obtain the greatest efficacy, VD3 supplementation should start at 
the pregnancy planning stage, under control of the VD3 serum concentration, which should exceed 30 ng/mL (75 nmol/L); 
this is to start the positive effect of the optimal VD3 concentration from the beginning of a pregnancy.
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INTRODUCTION
Vitamin D (VD) has two main forms: Vitamin D2 (VD2), 
produced by plants, and VD3, produced under influence of 
UVB radiation in animal skin. They both have the same bio-
logical action and vary only in their side-chain structure. Be-
cause of its pleiotropic actions, VD3 plays an important role 
in the human body. The discovery of VD3 was a result of the 
investigation on the cause of rickets at the beginning of the 
20th century. In recent years available data suggests a con-
nection between low levels of VD3 and the development of 
cancers, and cardiovascular and autoimmune diseases [1].
VD3 is synthesised from 7-dehydrocholesterol in the 
cortical layer of the epidermis under the influence of 290– 
–315 nm wavelength UVB radiation. Many factors such 
as geographic location, season, air pollution, skin colour, 
and age affect VD3 synthesis. The largest amount of UVB 
radiation able to induce synthesis of VD3 occurs around 
the equator, and it decreases when approaching the poles. 
In Poland, VD3 synthesis is almost impossible from Oc-
tober to March, and in the remaining months, 60% of 
the UVB radiation able to induce synthesis of VD3 occurs 
between 11 AM and 3 PM. VD3 is a secosteroid prohor-
mone which undergoes activation by 25-hydroxylation 
and 1α-hydroxylation, respectively, in the liver and the 
kidneys as well as in other tissues. The active form of VD3, 
1.25(OH)D3, is known as calcitriol. Serum VD3 level is mea-
sured based on the 25(OH)D3 concentration because it has 
a half-life 1000 times higher than 1.25(OH)D3. Calcitriol 
affects target cells after binding with the specific steroidal 
VD receptor (VDR). After binding with calcitriol, VDR creates 
a heterodimer with retinoid receptor X (RXR) which binds 
with VD responsive elements on DNA (VDRE), affecting 
transcription of many genes [2]. 
It is accepted that the minimal 25(OH)D3 serum level 
which enables optimal functioning of the human body is 
30 ng/mL (75 nmol/L). This concentration was based on the 
dependence of the VD3 and parathormone concentration, 
intestinal calcium absorption and bone density measure-
ments. VD3 deficiency can affect about 30% of the world’s 
population. In Poland, the study of Płudowski et al. [3], from 
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2014 showed that almost 90% of the investigated popula-
tion had a 25(OH)D3 level below the optimal 30 ng/mL level.
VD3 influences pregnancy development from the time 
of implantation. An increase in calcitriol concentration is 
observed from 10–12 weeks of gestation and grows two- 
to threefold until the end of pregnancy [4]. A large part of 
this increase is due to the expression of 1α-hydroxylase in 
the chorion and placenta [5]. Calcitriol helps in the trans-
formation of endometrial cells into decidual cells, promotes 
a human trophoblast invasion in vitro, and increases the 
expression of HOXA10, a gene necessary in the implanta-
tion process, and marrow differentiation in early gestation 
[6]. The expression of VDR and CYP27B1 in the chorion and 
placenta is greatest in the first and second trimesters, which 
proves the high demand for VD3 at the beginning of the 
pregnancy [7]. In the maintenance of a proper pregnancy, 
a state of transient immunosuppression is necessary, so the 
mother’s immune system does not reject foreign antigens 
of the embryo and the fetus. VD3 modulates actions of the 
immune system by regulating synthesis of cytokines and 
inhibiting proliferation of pro-inflammatory cells. Calcitriol 
directly influences the naive CD4+ lymphocytes, inhibit-
ing their differentiation into Th1 lymphocytes (synthesis 
of pro-inflammatory cytokines such as IFNγ), while pro-
moting differentiation into Th2 lymphocytes (synthesis of 
anti-inflammatory such as IL-4, IL-5, IL-10). VD3 also inhibits 
lymphocyte B synthesis and production of immunoglobulin 
type G. In a human syncytiotrophoblast, VD3 regulates, in 
an autocrine manner, synthesis of human chorionic go-
nadotropin (hCG), human placental lactogen (hPL), estra-
diol, and progesterone. These hormones help pregnancy 
to develop and stimulate growth and development of the 
placenta [8, 9].
VD3 AND ReCURReNT pRegNANCy lOSS
In recent years, the importance of impaired function of 
the immune system in the physiopathology of recurrent 
pregnancy loss (RPL) is being increasingly recognised. There 
is elevation of NK CD56+ cells as a percentage of total pe-
ripheral lymphocytes in the serum of women with recurrent 
pregnancy loss [10]. Also, there is a strong immunological 
response of Th1 lymphocytes, which produce pro-inflam-
matory cytokines and increase cytotoxicity of NK cells [11].
VD3, because of its immunomodulatory potential, 
can exert a positive effect on implantation and develop-
ment of early gestation. A meta-analysis from 2018, which 
included 2700 women (11 studies), assessed the influence 
of VD3 concentration on assisted reproductive treatment. 
In this study, VD3 concentration higher than 30 ng/mL was 
associated with greater chances of getting a positive preg-
nancy test, clinical pregnancy and giving birth to a healthy 
newborn. Therefore, investigators highlight the possible 
positive effects of VD3 supplementation in groups of wom-
en who undergo assisted reproductive treatment [12]. 
The study of Ota et al. [13], conducted on a group of 
133 women with a history of three or more pregnancy losses, 
has shown that 47.7% of women had VD3 deficiency, which 
was correlated with increased cell immunity and autoimmu-
nization. Similar results were obtained by Chen et al. [14], in 
a group of 99 women with a history of recurrent pregnancy 
loss, when VD3 deficiency was measured in 64.6% of the 
cases and was associated with an adverse immunological 
profile: increased concentration of the T helper lymphocytes 
synthesizing TNF α, lymphocytes CD19+ and NK cells. More-
over, in this study, supplementation of calcitriol (0.5 ug) for 
two months was reversing an adverse immunological pro-
file. Expression of VDR in the endometrium of women with 
recurrent pregnancy loss was also analysed. The study of 
Tavakoli et al. did not show any difference in the expression 
of VDR in the endometrium of the women with recurrent 
pregnancy loss in comparison to the healthy controls [15]. 
In two other studies, chorion expression of VDR was lower 
in women with a history of recurrent pregnancy loss in 
comparison to healthy controls [16, 17]. The European So-
ciety of Human Reproduction and Embryology, in recom-
mendations from 2018 regarding recurrent pregnancy loss, 
advises prophylactic VD3 supplementation, although it does 
not advise routine determination of serum concentration 
of 25(OH)D3 [18].
Although there is no randomised control trial (RCT) on 
the effectiveness of VD3 supplementation in the prevention 
of miscarriages, most data suggest that it has positive effect 
of immunological profile, which promotes implantation and 
development of early gestation.
VD3 and preeclampsia
In Scandinavia, more frequent occurrence of preeclamp-
sia (PE) in the winter months was observed, this later be-
ing proved in many population studies. This correlation 
was explained by the local lower skin synthesis of VD3 in 
the winter months [19]. Nowadays, many observational 
studies and meta-analyses are showing that low maternal 
VD3 serum concentration is related with greater risk of PE. 
In a meta-analysis from 2018 which included 23 studies, 
a serum level of 25(OH)D3 below 20 ng/mL was associated 
with greater risk of PE [20]. VD3 can also affect blood pres-
sure by inhibiting renin synthesis by the kidney capsular 
apparatus which was shown in the in vitro study [21]. Growth 
and development of the placenta is affected by VD3, and 
its deficiency is associated with PE, simultaneously in PE, 
placental synthesis of VD3 is decreased. Trophoblasts iso-
lated from women with PE had only 1/10th the activity of 
1α hydroxylase in comparison to the trophoblasts isolated 
from healthy controls [22]. VDR expression is also signifi-
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cantly lower in placentas from women with PE [23]. There 
were several studies on the effects of VD3 supplementation 
on PE occurrence. In a meta-analysis conducted by Fogacci 
et al. [24] in 2019, supplementation of VD3 significantly 
reduced the risk of PE OR (0.37, 95% CI: 0.26, 0.52). A Co-
chrane meta-analysis, also from 2019, showed that VD3 only 
supplementation decreases the risk of PE (RR 0.48, four 
studies conducted on a group of 499 women) [25]. Most 
data suggest that VD3 reduces the risk of PE in the general 
population. Royal College of Obstetricians and Gynaecolo-
gists for women with high risk of PE advises intake of at least 
800 IU daily combined with calcium [26].
VD3 and fetal growth
VD deficiency can disturb the process of formation and 
growth of the placenta, which can subsequently lead to in-
trauterine growth restriction (IUGR). In placentas from preg-
nancies complicated by IUGR, lower expression of VDR was 
observed [27]. Studies focused on proving the correlation 
between VD3 deficiency and higher IUGR occurrence have 
not found clear results. Some, like a study from 2019 con-
ducted in Iran on a group of 812 women [28], or a multi-
center study conducted on a group of 2,146 women from 
the USA [29], have shown that VD3 deficiency was associated 
with lower body weight in the newborns — a meta-analysis 
from 2013 showed such a correlation [30]. However, a study 
conducted in Norway in a group of 712 women from differ-
ent ethnic groups showed that VD3 is not an independent 
factor affecting differences between them in anthropomet-
ric parameters of the newborns and birth weight [31]. There 
is also inconsistency in data about the effects of VD3 supple-
mentation on birth weight. Two meta-analyses have shown 
that VD3 supplementation increases mean birth weight of 
newborns and decreases the risk of small for gestational 
age fetus (SGA) [32, 33]. On the other hand, the opposite 
result was found by Roth et al. [34], in an RCT conducted 
in Bangladesh on different doses of VD3 supplementation 
during pregnancy and lactation. There were no effects on 
height and birth weight of the newborns, or SGA occur-
rence in any of the tested groups. However, in this study 
supplementation was started between 17 and 24 weeks of 
gestation, which might be too late to obtain a maximal posi-
tive effect of optimal VD3 level on pregnancy development.
It is controversial whether VD3 supplementation has 
a positive effect on birth weight. Further studies are needed 
in order to help explain current contradictions within the 
existing body of knowledge. 
VD3 and gestational diabetes
VD3 plays an important role in carbohydrate metabolism; 
a positive correlation between VD3 concentration and tissue 
insulin sensitivity has been shown. VD3 deficiency diminishes 
insulin secretion by pancreatic β cells [35]. The insulin gene 
has a VDRE in a promoter region, so calcitriol can modulate 
insulin transcription. As previously mentioned, immune dis-
orders lead to a general inflammatory state, which is an im-
portant element in the development of insulin resistance 
and diabetes type 2. Interestingly, in placentas from women 
with gestational diabetes, VDR expression was higher than in 
healthy controls. In the same study, it was found that lower 
concentration of VD3 was associated with higher expres-
sion of VDR in the placenta [36]. There are many studies on 
VD3 concentration and supplementation on gestational 
diabetes occurrence. A meta-analysis from 2018, consisting 
of 87 observational studies and 25 randomized clinical tri-
als, which included, respectively, 55,859 and 2,445 women, 
showed that in a group of women with gestational diabetes, 
VD3 serum concentration was lower than in a healthy control 
group [37]. The same meta-analysis regarding the effects of 
VD3 supplementation on pregnancy development found 
that it reduces the risk of gestational diabetes [25, 30], but 
also that some studies included found no influence [38].
While there is strong theoretical background, the effec-
tiveness of VD3 supplementation on gestational diabetes 
is debatable.
VD3 and preterm labor
VD3 deficiency can affect preterm labor in two 
ways. Firstly, it reduces the body’s defense capability, and 
secondly, it increases synthesis of pro-inflammatory cy-
tokines. Uterine activity is probably triggered by genetic 
factors and pro-inflammatory cytokines. When they are 
activated before the fetus reaches maturity, preterm labor 
occurs. VD3 stimulates the innate immune system, which 
acts immediately after coming in contact with a pathogen. 
In experimental studies, calcitriol induces synthesis of cat-
helicidin (peptide of bactericidal properties) in myeloid cells, 
bronchial epithelial cells and keratinocytes. The immunos-
timulation by 25(OH)D3 also acts in an autocrine manner. 
Macrophages, after encountering a pathogen, increase the 
expression of VDR and CYP27B1 [39]. In many studies it has 
been demonstrated that VD3 deficiency can increase the 
risk of preterm birth. Among them, a study conducted by 
McDonnell et al. [40], showed that women with an optimal 
concentration of VD3 had 60% lower risk of preterm birth 
occurrence. In addition, a meta-analysis from 2017 sug-
gested a possible correlation between VD3 deficiency and 
preterm birth, and a probable positive effect of VD3 supple-
mentation on this pregnancy condition [41]. In the USA, 
the highest percentage of preterm births, 13.3%, occurs 
among Afro-American women, in comparison to 9.0% in 
the Caucasian population. This difference is still seen after 
adjusting for socioeconomic factors. African-Americans also 
have five times greater risk of recurrent preterm birth. At the 
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same time, in this group, VD3 deficiency occurs more often 
than in different ethnic groups [42, 43].
Presented studies are in favor that VD3 supplementa-
tion reduces the risk of preterm labor, however, we could 
not find specific recommendations on it.
VD3 during lactation ad postpartum period
The intake of 400 IU of VD3 is recommended for born 
in term infants between 0–6 months of life, independently 
to the way of the feeding, to prevent rickets. Exclusively 
breastfed infants are the group with the highest risk of vita-
min D deficiency because 25(OH)D3 concentration in breast 
milk is only about 20% of mothers’ serum concentration. So, 
to meet newborn requirements, mothers would have to 
have a serum concentration of VD3 much higher than it is 
usually recommended. The study of Hollis et al. [44], inves-
tigated this topic and concluded that a mother’s intake of 
6400 IU/day safely supplies breast milk with 25(OH)VD3 to 
satisfy her nursing infant’s requirements. Furthermore, an-
other important issue of VD3 supplementation is prevention 
of pregnancy-associated osteoporosis. It is a rare syndrome 
affecting women during late pregnancy and the early post 
pregnancy period. It can cause severe loss of bone mineral 
density, pathological fractures in the vertebrae, hip and 
other bones. In the study of Eroglu et al. [45], the levels of 
25(OH)D3, in postpartum women, were significantly lower 
in the low Bone Mineral Density group.
Proper VD3 supplementation during post-partum pe-
riod is important in terms of prevention of infant rickets and 
mothers’ osteoporosis in postpartum period.
SUMMARy
VD3 and VDR have an impact on pregnancy develop-
ment in many areas. In early gestation they play a key role 
in the formation of the chorion, modulate the immune 
response, and regulate blood pressure and glucose tol-
erance. Contemporary lifestyle, which involves spending 
a long time indoors, because UVB radiation does not pen-
etrate glass, makes VD3 skin synthesis difficult to occur in 
a sufficient amount. Nowadays, the Sars-CoV-2 pandemic 
can only increase the frequency of such a lifestyle. By proper 
VD3 supplementation and changes in lifestyle, it is possible 
to reduce the risk of many pregnancy complications. Treat-
ment of VD3 deficiency should start at the time of pregnancy 
planning. The best way to treat VD3 deficiency is by dietary 
supplements. Because of high individual variability of skin 
synthesis, it is difficult to advise/prescribe a specified dura-
tion of sun exposure to treat VD3 deficiency [2]. VD3 sup-
plementation in pregnancy seems to be a safe method to 
decrease VD3 deficiency, without side effects or intoxication. 
Many of the institutions give recommendations in this topic 
but they differ significantly in the advised dosage as listed in 
the Table 1. Most of them are consistent that a blood level of 
25(OH)D3 above 30 ng/mL should be maintained [46, 47]. 
At the same time routine measurement of 25(OH)D3 is not 
advised, however, in our opinion it is worth to consider 
especially in a women with a higher risk of the pregnancy 
complications such as: RPL, PE, fetal growth disturbances, 
pregnancy diabetes and preterm labor. They might benefit 
the most of the VD3 supplementation adjusted to the serum 
level of 25(OH)D3. 
Table 1. Reference intake of VD3 during pregnancy and lactation according to health authorities
Date Health Authority Dosage of VD3 supplementation in IU daily Comments Citation
2011 Endocrine Society 600 “in some cases at least 1500–2000 IU may be needed” [46]
2011 The Institute of Medicine 600 [48]
2011 American College of Obstetricians and Gynaecologists 600 1000–2000 IU daily when VD3 deficiency is identified [49]
2012 The German Nutrition Society 800 [50]
2014 Royal College of Obstetricians and Gynaecologists 400
800 IU daily, combined with calcium, 
recommended for women at high risk 
of PE 1000 IU daily recommended 
for women at high risk of VD3 deficiency1
[26]
2016 The Scientific Advisory Comittee on Nutrition 400 [51]
2020 The Polish Society of Gynecologists and Obstetrics 1500–2000
Women with a BMI > 30 kg/m2 are advised 
to consider a dosage of 4000 IU daily [47]
2020 The World Health Organization Oral VD3 supplementation is not recommended
Women with suspected VD3 deficiency 
are recommended to take 200 IU daily [52]
VD3 —  vitamin D3; IU — international unit; BMI — body mass index; 1Women with increased skin pigmentation, reduced exposure to sunlight, or those who are socially 
excluded or obese
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